Zoetis Inc. $ZTS Shares Sold by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC lowered its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 4.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 231,620 shares of the company’s stock after selling 9,547 shares during the period. Chevy Chase Trust Holdings LLC owned approximately 0.05% of Zoetis worth $33,891,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Halbert Hargrove Global Advisors LLC increased its holdings in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the period. Financial Consulate Inc. acquired a new stake in Zoetis in the third quarter worth about $39,000. SJS Investment Consulting Inc. lifted its holdings in Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after purchasing an additional 257 shares during the period. TruNorth Capital Management LLC bought a new position in Zoetis in the 3rd quarter valued at about $42,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in Zoetis in the 3rd quarter valued at about $46,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Ratings Changes

ZTS has been the topic of a number of recent analyst reports. BTIG Research restated a “buy” rating and set a $160.00 price target on shares of Zoetis in a research report on Thursday, February 26th. Bank of America increased their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research note on Monday, December 15th. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Finally, Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Six investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, Zoetis has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Price Performance

Shares of NYSE ZTS opened at $115.62 on Monday. Zoetis Inc. has a twelve month low of $114.47 and a twelve month high of $172.23. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The firm has a 50-day moving average of $125.34 and a two-hundred day moving average of $131.58. The company has a market capitalization of $48.81 billion, a price-to-earnings ratio of 19.21, a PEG ratio of 1.76 and a beta of 0.95.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same quarter in the previous year, the company posted $1.40 EPS. The business’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.8%. Zoetis’s payout ratio is 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.